Pomerantz’s Managing Partner Jeremy Lieberman oversees all the Firm’s litigations, strategizing for and leading cases that effect ground-breaking expansions of investor rights. He led the securities class action, In re Petrobras Securities Litigation, in which Pomerantz, as sole Lead Counsel, achieved a historic $3 billion settlement for defrauded investors in 2018. The case arose from a multi-billion-dollar kickback and bribery scheme involving Brazil’s oil giant, Petróleo Brasileiro S.A. – Petrobras. The Petrobras settlement is the largest securities class action settlement in a decade, the largest settlement ever in a securities class action involving a foreign issuer, the fifth-largest securities class action settlement ever achieved in the United States, the largest securities class action settlement achieved by a foreign Lead Plaintiff, and the largest securities class action settlement in history not involving a restatement of financial reports.
When the Supreme Court’s 2010 decision in Morrison v. Nat’l Australia Bank barred purchasers of securities on non-U.S. exchanges from pursuing claims in U.S. courts under the federal securities laws, Jeremy responded by developing novel legal strategies. Morrison presented a daunting hurdle for institutional investors, who increasingly invest in securities both in the U.S. and abroad. In litigation against pharmaceutical behemoth Perrigo Co. plc, Jeremy achieved a critical victory in November 2019, when the U.S. District Court for the District of New Jersey certified classes of investors that purchased Perrigo securities on both the New York Stock Exchange (“NYSE”) and the Tel Aviv Stock Exchange (“TASE”) – the first time that a U.S. district court has certified a class of investors on a non-U.S. exchange since Morrison.
Jeremy continued to expand the rights of global investors in Clal Insurance Company Ltd. v. Teva Pharmaceutical Industries Ltd., when a district court agreed to exercise supplemental jurisdiction over Israeli law claims on behalf of the Firm’s clients that had bought shares of Teva, Inc. on both the NYSE and the TASE.
In 2020, Jeremy won a Distinguished Leader award from the New York Law Journal. He was named a Leading Lawyer by The Legal 500 in 2020 and 2021. Lawdragon named Jeremy among the Leading 500 Lawyers in the United States in 2021 as well as a Leading Plaintiff Financial Attorney from 2019 to 2021. Jeremy has been honored as a Super Lawyers® “Top-Rated Securities Litigation Attorney” from 2016 through 2021. In 2019 he was Benchmark Litigation’s Plaintiff Attorney of the Year and in 2018 he was honored as a Law360 Titan of the Plaintiffs’ Bar.
Updated Sep 2021